Table of Contents
PHILADELPHIA — Lannett Co. has started rolling out its recently approved oxycodone hydrochloride oral solution (100 mg per 5 ml) earlier than expected.
Arthur Bedrosian, president and chief executive officer of Lannett, stated Monday that the company had expected to begin marketing the product in the second half of its fiscal year.
Lannett announced earlier this month that its oxycodone hydrochloride oral solution was approved by the Food and Drug Administration.
"The earlier than anticipated launch, combined with continued strong sales of our Digoxin product in the first quarter, provide us with additional confidence to reaffirm our financial guidance for the fiscal 2015 full year," Bedrosian said in a statement.
Oxycodone hydrochloride oral solution is an opioid pain medication indicated for the treatment of moderate to severe pain. At average wholesale price (AWP), the medication’s annualized sales are $43 million, according to IMS Health data reported by Lannett.
